ERBB2 and neoplasm: A retrospective cohort study that included 1099 women ≤35 years of age reported that HR-/HER2+ tumours had a significantly higher 10-year local recurrence rate compared to other subtypes (HR = 20.4; 95% CI: 11.8–35.4), irrespective of breast-conserving surgery or mastectomy treatment [237].